— Know what they know.
Not Investment Advice

TMCI NASDAQ

Treace Medical Concepts, Inc.
1W: +13.9% 1M: -1.8% 3M: +10.2% YTD: +76.8% 1Y: -34.9% 3Y: -54.8% 5Y: -82.0%
$4.55
+0.13 (+2.94%)
After Hours: $4.28 (-0.27, -5.93%)
Weekly Expected Move ±8.2%
$4 $4 $4 $5 $5
NASDAQ · Healthcare · Medical - Devices · Tech Score Buy · Power 53 · $295.9M mcap · 48M float · 1.21% daily turnover · Short 23% of daily vol
Credit Risk of going bust: higher than 81% of companies Debt: 20.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.16 (down 97%), Treace Medical Concepts, Inc. would be worth roughly what it owes.
Total debt $72.7M against a stock market value of $287.5M.
Distance to default 2.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $31.2M (short-term plus half of long-term), stock volatility 88.8%; Altman Z 0.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider+$1.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$295.9M
52W Range1.17-6.91
Volume180,869
Avg Volume577,571
Beta1.49
Dividend—
Analyst Ratings
2 Buy 6 Hold 1 Sell
Consensus Hold
Company Info
CEOJohn T. Treace
Employees450
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-04-23
Websitetreace.com
100 Palmetto Park Place
Ponte Vedra, FL 32081
US
904 373 5940
About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
Elder Scot Michael F-InKind 25,457 — 2026-09-30
Treace John T. P-Purchase 11,000 $4.34 2026-08-24
Treace John T. P-Purchase 5,000 $4.35 2026-08-21
Treace John T. P-Purchase 39,944 $4.44 2026-08-20
Hair Mark F-InKind 37,102 — 2026-08-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms